eprintid: 10188451
rev_number: 9
eprint_status: archive
userid: 699
dir: disk0/10/18/84/51
datestamp: 2024-03-05 12:01:09
lastmod: 2024-03-05 12:01:09
status_changed: 2024-03-05 12:01:09
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Yildirim, Resit
creators_name: Oliveira, Tatiana
creators_name: Isenberg, David Alan
title: Approach to vaccination in systemic lupus erythematosus on biological treatment
ispublished: pub
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
keywords: Science & Technology, Life Sciences & Biomedicine, Rheumatology, Lupus Erythematosus, Systemic, Rituximab, Immune System Diseases, INFLUENZA VACCINATION, RHEUMATOID-ARTHRITIS, HERPES-ZOSTER, PNEUMOCOCCAL VACCINATION, POLYSACCHARIDE VACCINE, ANTIBODY-RESPONSES, IMMUNOGENICITY, SAFETY, IMMUNIZATION, AUTOIMMUNE
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions
abstract: In recent years, treat-to-target strategy and early intervention strategies with immunosuppressive agents have attempted to improve the prognosis and outcome in patients with autoimmune inflammatory rheumatic diseases. However, infectious complications due to side effects of medication remain a major concern in routine practice. In this regard, vaccine immunity and vaccination programmes are of the utmost importance in patients with systemic lupus erythematosus (SLE) in terms of morbidity and mortality. Encouragingly, research investigations have increased exponentially, both in monitoring the vaccines efficacy, and in determining the immune response while patients are on immunosuppression., However, in this biological era in rheumatology, relatively little data have been published investigating these parameters in those receiving biological agents, therefore, no definitive consensus about a vaccination policy for patients with SLE is currently available. In this review, we aim to address what is established about vaccinating patients with SLE on biological agents and discuss potential problems.
date: 2023-06-19
date_type: published
publisher: BMJ PUBLISHING GROUP
official_url: http://dx.doi.org/10.1136/ard-2023-224071
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2033438
doi: 10.1136/ard-2023-224071
medium: Print-Electronic
pii: ard-2023-224071
lyricists_name: Isenberg, David
lyricists_id: DAISE40
actors_name: Isenberg, David
actors_name: Geary, Esther
actors_id: DAISE40
actors_id: ECGEA88
actors_role: owner
actors_role: impersonator
full_text_status: public
publication: Annals of the Rheumatic Diseases
volume: 82
number: 9
pagerange: 1123-1129
pages: 7
event_location: England
citation:        Yildirim, Resit;    Oliveira, Tatiana;    Isenberg, David Alan;      (2023)    Approach to vaccination in systemic lupus erythematosus on biological treatment.                   Annals of the Rheumatic Diseases , 82  (9)   pp. 1123-1129.    10.1136/ard-2023-224071 <https://doi.org/10.1136/ard-2023-224071>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10188451/1/Isenberg_lupus%20vaccination-CLEAN%20DOCUMENT-10%20may.pdf